FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016116742> ?p ?o ?g. }

• W2016116742 abstract "You have accessJournal of UrologyProstate Cancer: Basic Research1 Apr 2011606 CARBIDOPA ENHANCES ANTITUMORAL ACTIVITY OF BICALUTAMIDE ON THE ANDROGEN RECEPTOR-AXIS IN CASTRATION-RESISTANT PROSTATE TUMORS Christian Thomas, Latif Wafa, Francois Lamoureux, Paul S. Rennie, and Martin E. Gleave Christian ThomasChristian Thomas Vancouver, Canada More articles by this author , Latif WafaLatif Wafa Vancouver, Canada More articles by this author , Francois LamoureuxFrancois Lamoureux Vancouver, Canada More articles by this author , Paul S. RenniePaul S. Rennie Vancouver, Canada More articles by this author , and Martin E. GleaveMartin E. Gleave Vancouver, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.1459AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The identification of novel agents or combination therapies for castration-resistant prostate cancer (CRPC) remains a major challenge in prostate cancer drug development. A long-lasting response to bicalutamide, currently standard treatment after castration failure, is limited by its partially agonistic effects. Carbidopa is a potent drug that inhibits coactivation function of the androgen-receptor (AR) coactivator protein, L-dopa decarboxylase, and has previously been shown to retard prostate tumor growth and PSA production in xenograft experiments. In the current study, we hypothesize that pharmacological targeting of the AR-axis by combination treatment of bicalutamide plus carbidopa significantly enhances the antitumoral activity in vitro and in vivo compared to single use of each drug. METHODS Carbidopa was tested for its ability to enhance the effects of bicalutamide in cell viability assays and PSA transactivation by luciferase assay in LNCaP and C4-2 cells. For in vivo xenograft studies, LNCaP cells were inoculated s.c. in athymic nude mice. Mice were castrated and after CRPC progression randomily assigned to treatments with carbidopa (50mg/kg) and bicalutamide (50mg/kg) as monotherapy or in combination. Tumor volume and serum PSA were evaluated weekly. RESULTS Combination treatment of carbidopa plus bicalutamide significantly inhibited cell growth for both LNCaP and C4-2 cells. More specifically, in LNCaP cells, bicalutamide mono treatment inhibited cell growth by 48%, while the combination treatment reduced cell growth by 62% compared to control. Similarly in C4-2 cells, bicalutamide mono and combination treatments inhibited cell growth by 49% and 68%, respectively. The combination treatment also decreased androgen-induced PSA transactivation by 75% in LNCaP cells and by 65% in C4-2 cells compared to control, while bicalutamide mono therapy only reduced PSA levels by 27% (LNCaP) and 29% (C4-2). In vivo, bicalutamide mono delayed the growth rate of LNCaP CRPC tumors by 3.2-fold, while combination treatment reduced tumor growth by 6.8-fold compared to control. Serum PSA production was also reduced 2.5-fold with bicalutamide mono treatment, while the combination therapy reduced PSA progression by 4.3-fold compared to control. CONCLUSIONS This study reports preclinical proof-of-principle that pharmacological targeting of CRPC tumors by combination treatment of bicalutamide plus carbidopa significantly reduces AR activity, and thereby delays tumor progression in vivo. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e244 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Metrics Author Information Christian Thomas Vancouver, Canada More articles by this author Latif Wafa Vancouver, Canada More articles by this author Francois Lamoureux Vancouver, Canada More articles by this author Paul S. Rennie Vancouver, Canada More articles by this author Martin E. Gleave Vancouver, Canada More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2016116742 created "2016-06-24" @default.
• W2016116742 creator A5008699306 @default.
• W2016116742 creator A5011209723 @default.
• W2016116742 creator A5050943523 @default.
• W2016116742 creator A5062125605 @default.
• W2016116742 creator A5065365130 @default.
• W2016116742 date "2011-04-01" @default.
• W2016116742 modified "2023-10-18" @default.
• W2016116742 title "606 CARBIDOPA ENHANCES ANTITUMORAL ACTIVITY OF BICALUTAMIDE ON THE ANDROGEN RECEPTOR-AXIS IN CASTRATION-RESISTANT PROSTATE TUMORS" @default.
• W2016116742 doi "https://doi.org/10.1016/j.juro.2011.02.1459" @default.
• W2016116742 hasPublicationYear "2011" @default.
• W2016116742 type Work @default.
• W2016116742 sameAs 2016116742 @default.
• W2016116742 citedByCount "0" @default.
• W2016116742 crossrefType "journal-article" @default.
• W2016116742 hasAuthorship W2016116742A5008699306 @default.
• W2016116742 hasAuthorship W2016116742A5011209723 @default.
• W2016116742 hasAuthorship W2016116742A5050943523 @default.
• W2016116742 hasAuthorship W2016116742A5062125605 @default.
• W2016116742 hasAuthorship W2016116742A5065365130 @default.
• W2016116742 hasConcept C104317684 @default.
• W2016116742 hasConcept C121608353 @default.
• W2016116742 hasConcept C126322002 @default.
• W2016116742 hasConcept C1292079 @default.
• W2016116742 hasConcept C134018914 @default.
• W2016116742 hasConcept C143998085 @default.
• W2016116742 hasConcept C185592680 @default.
• W2016116742 hasConcept C2776551883 @default.
• W2016116742 hasConcept C2776754145 @default.
• W2016116742 hasConcept C2777899217 @default.
• W2016116742 hasConcept C2777911890 @default.
• W2016116742 hasConcept C2779134260 @default.
• W2016116742 hasConcept C2779723316 @default.
• W2016116742 hasConcept C2779734285 @default.
• W2016116742 hasConcept C2780192828 @default.
• W2016116742 hasConcept C2780304432 @default.
• W2016116742 hasConcept C2780962315 @default.
• W2016116742 hasConcept C502942594 @default.
• W2016116742 hasConcept C55493867 @default.
• W2016116742 hasConcept C61367390 @default.
• W2016116742 hasConcept C71315377 @default.
• W2016116742 hasConcept C71924100 @default.
• W2016116742 hasConcept C86339819 @default.
• W2016116742 hasConcept C98274493 @default.
• W2016116742 hasConceptScore W2016116742C104317684 @default.
• W2016116742 hasConceptScore W2016116742C121608353 @default.
• W2016116742 hasConceptScore W2016116742C126322002 @default.
• W2016116742 hasConceptScore W2016116742C1292079 @default.
• W2016116742 hasConceptScore W2016116742C134018914 @default.
• W2016116742 hasConceptScore W2016116742C143998085 @default.
• W2016116742 hasConceptScore W2016116742C185592680 @default.
• W2016116742 hasConceptScore W2016116742C2776551883 @default.
• W2016116742 hasConceptScore W2016116742C2776754145 @default.
• W2016116742 hasConceptScore W2016116742C2777899217 @default.
• W2016116742 hasConceptScore W2016116742C2777911890 @default.
• W2016116742 hasConceptScore W2016116742C2779134260 @default.
• W2016116742 hasConceptScore W2016116742C2779723316 @default.
• W2016116742 hasConceptScore W2016116742C2779734285 @default.
• W2016116742 hasConceptScore W2016116742C2780192828 @default.
• W2016116742 hasConceptScore W2016116742C2780304432 @default.
• W2016116742 hasConceptScore W2016116742C2780962315 @default.
• W2016116742 hasConceptScore W2016116742C502942594 @default.
• W2016116742 hasConceptScore W2016116742C55493867 @default.
• W2016116742 hasConceptScore W2016116742C61367390 @default.
• W2016116742 hasConceptScore W2016116742C71315377 @default.
• W2016116742 hasConceptScore W2016116742C71924100 @default.
• W2016116742 hasConceptScore W2016116742C86339819 @default.
• W2016116742 hasConceptScore W2016116742C98274493 @default.
• W2016116742 hasFunder F4320320879 @default.
• W2016116742 hasIssue "4S" @default.
• W2016116742 hasLocation W20161167421 @default.
• W2016116742 hasOpenAccess W2016116742 @default.
• W2016116742 hasPrimaryLocation W20161167421 @default.
• W2016116742 hasRelatedWork W1606103292 @default.
• W2016116742 hasRelatedWork W2058568096 @default.
• W2016116742 hasRelatedWork W24268339 @default.
• W2016116742 hasRelatedWork W2595758682 @default.
• W2016116742 hasRelatedWork W2740124347 @default.
• W2016116742 hasRelatedWork W2948523439 @default.
• W2016116742 hasRelatedWork W2954455697 @default.
• W2016116742 hasRelatedWork W3195984087 @default.
• W2016116742 hasRelatedWork W3198382015 @default.
• W2016116742 hasRelatedWork W4287355568 @default.
• W2016116742 hasVolume "185" @default.
• W2016116742 isParatext "false" @default.
• W2016116742 isRetracted "false" @default.
• W2016116742 magId "2016116742" @default.
• W2016116742 workType "article" @default.